Regulatory T-cell adoptive immunotherapy: Potential for treatment of autoimmunity

Expert Review of Clinical Immunology

Volumn 7, Issue 2, 2011, Pages 213-225

  Wright, Graham P ^a   Ehrenstein, Michael R ^a   Stauss, Hans J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Ag specific; autoimmunity; regulatory T cells; T cell receptor gene transfer

Indexed keywords

T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL EXPANSION; GENE TRANSFER; HUMAN; IMMUNOGENETICS; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; MODELS, ANIMAL; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES, REGULATORY;

EID: 79953114328     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.96     Document Type: Review

References (133)

1. + T cells. Adv. Immunol. 105, 99-130 (2010).
2. Saurer L, Mueller C. T cell-mediated immunoregulation in the gastrointestinal tract. Allergy 64, 505-519 (2009).
3. Smith TR, Kumar V. Revival of CD8+ Treg-mediated suppression. Trends Immunol. 29, 337-342 (2008).
4. Wildin RS, Ramsdell F, Peake J et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27, 18-20 (2001). (Pubitemid 32044512)
5. Gavin MA, Rasmussen JP, Fontenot JD et al. FoxP3-dependent programme of regulatory T-cell differentiation. Nature 445, 771-775 (2007). (Pubitemid 46279714)
6. + regulatory T cells. Nat. Immunol. 4, 330-336 (2003). (Pubitemid 36432314)
7. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor FoxP3. Science 299, 1057-1061 (2003). (Pubitemid 36222930)
8. + T cells. Immunity 25, 249-259 (2006). (Pubitemid 44224144)
9. Hsieh CS, Zheng Y, Liang Y, Fontenot JD, Rudensky AY. An intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires. Nat. Immunol. 7, 401-410 (2006).
10. + T cell receptors. Immunity 21, 267-277 (2004). (Pubitemid 39094055)
11. + immunoregulatory T cells is antigen nonspecific. J. Immunol. 164, 183-190 (2000). Demonstrates that Tregs can suppress conventional T cells of distinct specificity provided the cognate antigen (Ag) for both cell types are presented on the same or adjacent antigen-presenting cells. (Pubitemid 30012989)
12. + regulatory T cell function. Science 322, 271-275 (2008).
13. Fallarino F, Grohmann U, Hwang KW et al. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4, 1206-1212 (2003). (Pubitemid 37547898)
14. Huang CT, Workman CJ, Flies D et al. Role of LAG-3 in regulatory T cells. Immunity 21, 503-513 (2004). (Pubitemid 39370506)
15. Bopp T, Becker C, Klein M et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J. Exp. Med. 204, 1303-1310 (2007). (Pubitemid 46919868)
16. Deaglio S, Dwyer KM, Gao W et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265 (2007). (Pubitemid 46919862)
17. + regulatory T cell activity in both humans and mice. J. Immunol. 172, 834-842 (2004). (Pubitemid 38113739)
18. + regulatory cells within the central nervous system. J. Immunol. 175, 3025-3032 (2005). (Pubitemid 41170521)
19. Collison LW, Workman CJ, Kuo TT et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450, 566-569 (2007). (Pubitemid 350190247)
20. + T cells. Nat. Immunol. 8, 1353-1362 (2007). (Pubitemid 350131172)
21. + T regulatory cell-mediated suppression. Immunity 30, 636-645 (2009).
22. Waldmann H, Adams E, Fairchild P, Cobbold S. Infectious tolerance and the long-term acceptance of transplanted tissue. Immunol. Rev. 212, 301-313 (2006). (Pubitemid 44116716)
23. + regulatory T lymphocytes. Nat. Med. 14, 88-92 (2008).
24. + regulatory T cells. J. Immunol. 175, 4180-4183 (2005). (Pubitemid 41361949)
25. + regulatory T cells induce alternative activation of human monocytes/macrophages. Proc. Natl Acad. Sci. USA 104, 19446-19451 (2007).
26. Walker LS, Natural Treg in autoimmune diabetes: All present and correct? Expert Opin. Biol. Ther. 8, 1691-1703 (2008). Thorough review and discussion of the conflicting data regarding the role of Tregs in autoimmunity. Whilst thisreview focuses primarily on diabetes, the concepts can be readily extended to cover a broad range of autoimmune disorders.
27. Costantino CM, Baecher-Allan C, Hafler DA. Multiple sclerosis and regulatory T cells. J. Clin. Immunol. 28, 697-706 (2008).
28. Flores-Borja F, Mauri C, Ehrenstein MR. Restoring the balance: Harnessing regulatory T cells for therapy in rheumatoid arthritis. Eur. J. Immunol. 38, 934-937 (2008).
29. Gerli R, Nocentini G, Alunno A et al. Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun. Rev. 8, 426-430 (2009).
30. Ehrenstein MR, Evans JG, Singh A et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFa therapy. J. Exp. Med. 200, 277-285 (2004). (Pubitemid 39031247)
31. Huan J, Culbertson N, Spencer L et al. Decreased FoxP3 levels in multiple sclerosis patients. J. Neurosci. Res. 81, 45-52 (2005). (Pubitemid 41139109)
32. + CD25 (high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FoxP3-positive cells and reduced FoxP3 expression at the single-cell level. Immunology 123, 79-89 (2008). (Pubitemid 350255996)
33. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199, 971-979 (2004). (Pubitemid 38481088)
34. + T cells in patients with systemic lupus erythematosus. J. Immunol. 182, 1689-1695 (2009).
35. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431-440 (2000).
36. + regulatory T cells. Arthritis Rheum. 52, 2212-2221 (2005). (Pubitemid 40994344)
37. + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169, 4712-4716 (2002). (Pubitemid 35217131)
38. Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J. Immunol. 177, 1451-1459 (2006). (Pubitemid 44092478)
39. Tang Q, Henriksen KJ, Bi M et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199, 1455-1465 (2004). This study demonstrates that islet-specific Tregs, obtained from T-cell receptor (TCR)-transgenic mice, are capable of reverting ongoing diabetes. Importantly, the Tregs were specific for a single Ag, yet were able to suppress a complex multiepitope immune response. (Pubitemid 38780401)
40. + T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 199, 1467-1477 (2004). This study demonstrates that islet-specific Tregs, obtained from TCR-transgenic mice, are capable of reverting ongoing diabetes. Importantly, the Tregs were specific for a single Ag, yet were able to suppress a complex multi-epitope immune response. (Pubitemid 38780402)
41. + CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204, 191-201 (2007). (Pubitemid 46148769)
42. + Treg. Eur. J. Immunol. 39, 1108-1117 (2009). Using TCR-transgenic Tregs, this study demonstrated that Ag-specific Tregs were able to revert disease in a model of multiple sclerosis. This was achieved using Tregs with distinct specificity to the T cells initiating disease.
43. Ménétrier-Caux C, Gobert M, Caux C. Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res. 69, 7895-7898 (2009).
44. + regulatory T cells from nonobese diabetic mice. J. Immunol. 175, 3053-3059 (2005). (Pubitemid 41170524)
45. + T regulatory cells. J. Immunol. 178, 4062-4071 (2007). (Pubitemid 46492354)
46. + T reg cells. J. Exp. Med. 203, 1701-1711 (2006). (Pubitemid 44036276)
47. +CD25high regulatory cells in human peripheral blood. J. Immunol. 167, 1245-1253 (2001). (Pubitemid 32703119)
48. Gavin MA, Torgerson TR, Houston E et al. Single-cell analysis of normal and FoxP3-mutant human T cells: FoxP3 expression without regulatory T cell development. Proc. Natl Acad. Sci. USA 103, 6659-6664 (2006).
49. +CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 108, 4260-4267 (2006). (Pubitemid 44913302)
50. Fritzsching B, Oberle N, Pauly E et al. Naive regulatory T cells: A novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood 108, 3371-3378 (2006).
51. Valmori D, Merlo A, Souleimanian NE, Hesdorffer CS, Ayyoub M. A peripheral circulating compartment of natural naive CD4 Tregs. J. Clin. Invest. 115, 1953-1962 (2005). (Pubitemid 40979735)
52. Seddiki N, Santner-Nanan B, Martinson J et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 203, 1693-1700 (2006). (Pubitemid 44036275)
53. + Treg free of contaminating effector cells. Blood 113, 827-836 (2009).
54. + regulatory T cells in the steady state. J. Exp. Med. 198, 737-746 (2003). (Pubitemid 37087773)
55. + regulatory T cells in vivo. J. Exp. Med. 198, 249-258 (2003). (Pubitemid 36992178)
56. Mondino A, Mueller DL. mTOR at the crossroads of T cell proliferation and tolerance. Semin. Immunol. 19, 162-172 (2007). (Pubitemid 46810293)
57. + regulatory T cells. Blood 105, 4743-4748 (2005). (Pubitemid 40807298)
58. + regulatory T cells cultured with rapamycin. J. Immunol. 178, 320-329 (2007). (Pubitemid 46033615)
59. (+) T cells by inhibition of phospholipase D signaling. Nat. Methods 3, 629-636 (2006). (Pubitemid 44123430)
60. + regulatory T cells via a TGF-β and retinoic acid-dependent mechanism. J. Exp. Med. 204, 1757-1764 (2007). (Pubitemid 47236314)
61. + regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J. Immunol. 172, 6003-6010 (2004). (Pubitemid 38621201)
62. + regulatory T cells by TGF-β induction of transcription factor FoxP3. J. Exp. Med. 198, 1875-1886 (2003). (Pubitemid 38032120)
63. + regulatory T lymphocytes through the induction of anergy and infectious tolerance. J. Immunol. 180, 2830-2838 (2008).
64. Godebu E, Summers-Torres D, Lin MM, Baaten BJ, Bradley LM. Polyclonal adaptive regulatory CD4 cells that can reverse Type I diabetes become oligoclonal long-term protective memory cells. J. Immunol. 181, 1798-1805 (2008).
65. Weber SE, Harbertson J, Godebu E et al. Adaptive islet-specific regulatory CD4 T cells control autoimmune diabetes and mediate the disappearance of pathogenic Th1 cells in vivo. J. Immunol. 176, 4730-4739 (2006). Using islet-specific TCR-transgenic conventional T cells, this study demonstrated that induced adaptive Tregs were capable of reverting ongoing diabetes.
66. Huter EN, Stummvoll GH, DiPaolo RJ, Glass DD, Shevach EM. Cutting edge: Antigen-specific TGF b-induced regulatory T cells suppress Th17-mediated autoimmune disease. J. Immunol. 181, 8209-8213 (2008).
67. - T cells of healthy and Type 1 diabetic subjects. Eur. J. Immunol. 39, 612-620 (2009). Demonstrated that islet-specific adaptive Tregs could be induced from the peripheral blood of diabetic patients. The adaptive Tregs were equally efficient at suppression in vitro as those obtained from control samples.
68. Lal G, Zhang N, van der Touw W et al. Epigenetic regulation of FoxP3 expression in regulatory T cells by DNA methylation. J. Immunol. 182, 259-273 (2009).
69. + T regulatory cells. J. Immunol. 184(7), 3433-3441 (2010).
70. Stanislawski T, Voss RH, Lotz C et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2, 962-970 (2001). (Pubitemid 32976170)
71. Wright GP, Notley CA, Xue SA et al. Adoptive therapy with redirected primary regulatory T cells results in antigenspecific suppression of arthritis. Proc. Natl Acad. Sci. USA 6(45), 19078-19083 (2009).
72. Brusko TM, Koya RC, Zhu S et al. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One. 5, e11726 (2010). In this study, TCR gene transfer was utilized to generated a large population of functional Ag-specific human Tregs. This approach would be applicable to treat human autoimmune disease.
73. Amrani A, Verdaguer J, Serra P, Tafuro S, Tan R, Santamaria P. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 406, 739-742 (2000).
74. Kurokawa M, Kato T, Masuko-Hongo K et al. Characterisation of T cell clonotypes that accumulated in multiple joints of patients with rheumatoid arthritis. Ann. Rheum. Dis. 58, 546-553 (1999). (Pubitemid 29409100)
75. Luo W, Ma L, Wen Q, Wang N, Zhou MQ, Wang XN. Analysis of the interindividual conservation of T cell receptor a- and b-chain variable regions gene in the peripheral blood of patients with systemic lupus erythematosus. Clin. Exp. Immunol. 154, 316-324 (2008).
76. Somoza N, Vargas F, Roura-Mir C et al. Pancreas in recent onset insulindependent diabetes mellitus. Changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor V b usage, and cytokine profile. J. Immunol. 153, 1360-1377 (1994). (Pubitemid 24228529)
77. Hafler DA, Duby AD, Lee SJ, Benjamin D, Seidman JG, Weiner HL. Oligoclonal T lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 167, 1313-1322 (1988).
78. Voss RH, Kuball J, Engel R et al. Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression. Immunol. Res. 34, 67-87 (2006). (Pubitemid 43780377)
79. Bouneaud C, Kourilsky P, Bousso P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: A large fraction of T cell clones escapes clonal deletion. Immunity 13, 829-840 (2000). (Pubitemid 32041805)
80. Sadovnikova E, Stauss HJ. Peptidespecific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: Reagents for tumor immunotherapy. Proc. Natl Acad. Sci. USA 93, 13114-13118 (1996). (Pubitemid 26382778)
81. Thomas S, Stauss HJ, Morris EC. Molecular immunology lessons from therapeutic T-cell receptor gene transfer. Immunology 129, 170-177 (2010).
82. Szymczak AL, Workman CJ, Wang Y et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat. Biotechnol. 22, 589-594 (2004). (Pubitemid 38585911)
83. Setoguchi K, Misaki Y, Araki Y et al. Antigen-specific T cells transduced with IL-10 ameliorate experimentally induced arthritis without impairing the systemic immune response to the antigen. J. Immunol. 165, 5980-5986 (2000).
84. Fujio K, Okamoto A, Araki Y et al. Gene therapy of arthritis with TCR isolated from the inflamed paw. J. Immunol. 177, 8140-8147 (2006). (Pubitemid 44846333)
85. Fujio K, Okamoto A, Tahara H et al. Nucleosome-specific regulatory T cells engineered by triple gene transfer suppress a systemic autoimmune disease. J. Immunol. 173, 2118-2125 (2004). (Pubitemid 38971650)
86. Jaeckel E, von Boehmer H, Manns MP. Antigen-specific FoxP3-transduced T-cells can control established Type 1 diabetes. Diabetes 54, 306-310 (2005).
87. + Tregs. J. Clin. Invest. 115, 3276-3284 (2005). (Pubitemid 41567592)
88. + regulatory T cells. Int. Immunol. 16, 1643-1656 (2004).
89. + T regulatory cells by activationindependent expression of FoxP3. Mol. Ther. 16, 194-202 (2008).
90. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxP3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112, 2340-2352 (2008).
91. Beriou G, Costantino CM, Ashley CW et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 113, 4240-4249 (2009).
92. Zhou X, Bailey-Bucktrout SL, Jeker LT et al. Instability of the transcription factor FoxP3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10, 1000-1007 (2009). Using a double-transgenic mouse model, this study demonstrated that a minority population of Tregs could lose FoxP3 expression and switch to a pathogenic phenotype. These cells were capable of inducing diabetes. This is an important safety concern for adoptive Treg therapy that must be addressed before translation into the clinic can proceed.
93. + regulatory T cells upon repetitive in vitro stimulation. Eur. J. Immunol. 39, 1088-1097 (2009).
94. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (2006). (Pubitemid 44547756)
95. + regulatory T cells. Blood 107, 1018-1023 (2006). (Pubitemid 43156300)
96. Newrzela S, Cornils K, Li Z et al. Resistance of mature T cells to oncogene transformation. Blood 112, 2278-2286 (2008).
97. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: New answers to an old question. J. Immunol. 166, 973-981 (2001). (Pubitemid 32060253)
98. Davies JL, Kawaguchi Y, Bennett ST et al. A genome-wide search for human Type 1 diabetes susceptibility genes. Nature 371, 130-136 (1994). (Pubitemid 24284009)
99. Rigby AS, Silman AJ, Voelm L et al. Investigating the HLA component in rheumatoid arthritis: An additive (dominant) mode of inheritance is rejected, a recessive mode is preferred. Genet. Epidemiol. 8, 153-175 (1991).
100. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205-1213 (1987). (Pubitemid 18005792)
101. van der Helm-van Mil AH, Kern M, Gregersen PK, Huizinga TW. Variation in radiologic joint destruction in rheumatoid arthritis differs between monozygotic and dizygotic twins and pairs of unrelated patients. Arthritis Rheum. 54, 2028-2030 (2006). (Pubitemid 43877957)
102. Moreno I, Valenzuela A, García A, Yélamos J, Sánchez B, Hernánz W. Association of the shared epitope with radiological severity of rheumatoid arthritis. J. Rheumatol. 23, 6-9 (1996). (Pubitemid 26035992)
103. Forabosco P, Gorman JD, Cleveland C et al. Meta-analysis of genome-wide linkage studies of systemic lupus erythematosus. Genes Immun. 7, 609-614 (2006). (Pubitemid 44614877)
104. Fernando MM, Stevens CR, Walsh EC et al. Defining the role of the MHC in autoimmunity: A review and pooled analysis. PLoS Genet. 4, e1000024 (2008).
105. Congia M, Patel S, Cope AP, De Virgiliis S, Sønderstrup G. T cell epitopes of insulin defined in HLA-DR4 transgenic mice are derived from preproinsulin and proinsulin. Proc. Natl Acad. Sci. USA 95, 3833-3838 (1998). (Pubitemid 28173826)
106. Rudy G, Stone N, Harrison LC et al. Similar peptides from two b cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes. Mol. Med. 1, 625-633 (1995).
107. Kent SC, Chen Y, Bregoli L et al. Expanded T cells from pancreatic lymph nodes of Type 1 diabetic subjects recognize an insulin epitope. Nature 435, 224-228 (2005). (Pubitemid 40685950)
108. Alleva DG, Crowe PD, Jin L et al. A disease-associated cellular immune response in Type 1 diabetics to an immunodominant epitope of insulin. J. Clin. Invest. 107, 173-180 (2001). (Pubitemid 32096833)
109. Nepom GT, Lippolis JD, White FM et al. Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65). Proc. Natl Acad. Sci. USA 98, 1763-1768 (2001). (Pubitemid 32165572)
110. Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL, Maclaren NK. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J. Clin. Invest. 94, 2125-2129 (1994). (Pubitemid 24348254)
111. Endl J, Otto H, Jung G et al. Identification of naturally processed T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients. J. Clin. Invest. 99, 2405-2415 (1997). (Pubitemid 27227718)
112. Boyton RJ, Lohmann T, Londei M et al. Glutamic acid decarboxylase T lymphocyte responses associated with susceptibility or resistance to Type I diabetes: Analysis in disease discordant human twins, non-obese diabetic mice and HLA-DQ transgenic mice. Int. Immunol. 10, 1765-1776 (1998). (Pubitemid 28566038)
113. Herman AE, Tisch RM, Patel SD et al. Determination of glutamic acid decarboxylase 65 peptides presented by the Type I diabetes-associated HLA-DQ8 class II molecule identifies an immunogenic peptide motif. J. Immunol. 163, 6275-6282 (1999).
114. Reijonen H, Elliott JF, van Endert P, Nepom G. Differential presentation of glutamic acid decarboxylase 65 (GAD65) T cell epitopes among HLA-DRB1*0401- positive individuals. J. Immunol. 163, 1674-1681 (1999). (Pubitemid 29352793)
115. Peakman M, Stevens EJ, Lohmann T et al. Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4. J. Clin. Invest. 104, 1449-1457 (1999).
116. Honeyman MC, Stone NL, Harrison LC. T-cell epitopes in Type 1 diabetes autoantigen tyrosine phosphatase IA-2: Potential for mimicry with rotavirus and other environmental agents. Mol. Med. 4, 231-239 (1998). (Pubitemid 28331640)
117. Hawkes CJ, Schloot NC, Marks J et al. T-cell lines reactive to an immunodominant epitope of the tyrosinephosphatase-like autoantigen IA-2 in Type 1 diabetes. Diabetes 49, 356-366 (2000). (Pubitemid 30131780)
118. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346, 183-187 (1990).
119. Trotter JL, Pelfrey CM, Trotter AL et al. T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects. J. Neuroimmunol. 84, 172-178 (1998). (Pubitemid 28248403)
120. Forsthuber TG, Shive CL, Wienhold W et al. T cell epitopes of human myelin oligodendrocyte glycoprotein identified in HLA-DR4 (DRB1*0401) transgenic mice are encephalitogenic and are presented by human B cells. J. Immunol. 167, 7119-7125 (2001). (Pubitemid 33144209)
121. van Noort JM, van Sechel AC, Bajramovic JJ et al. The small heat-shock protein a B-crystallin as candidate autoantigen in multiple sclerosis. Nature 375, 798-801 (1995).
122. Ousman SS, Tomooka BH, van Noort JM et al. Protective and therapeutic role for aB-crystallin in autoimmune demyelination. Nature 448, 474-479 (2007). (Pubitemid 47123511)
123. Londei M, Savill CM, Verhoef A et al. Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc. Natl Acad. Sci. USA 86, 636-640 (1989). (Pubitemid 19037795)
124. Kim HY, Kim WU, Cho ML et al. Enhanced T cell proliferative response to type II collagen and synthetic peptide CII (255-274) in patients with rheumatoid arthritis. Arthritis Rheum. 42, 2085-2093 (1999).
125. Dzhambazov B, Holmdahl M, Yamada H et al. The major T cell epitope on type II collagen is glycosylated in normal cartilage but modified by arthritis in both rats and humans. Eur. J. Immunol. 35, 357-366 (2005). (Pubitemid 40331311)
126. Verheijden GF, Rijnders AW, Bos E et al. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum. 40, 1115-1125 (1997). (Pubitemid 27242299)
127. Cope AP, Patel SD, Hall F et al. T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritisassociated and nonassociated HLA-DR4 alleles. Arthritis Rheum. 42, 1497-1507 (1999). (Pubitemid 30265609)
128. Feitsma AL, van der Voort EI, Franken KL et al. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum. 62, 117-125 (2010).
129. Kaliyaperumal A, Mohan C, Wu W, Datta SK. Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J. Exp. Med. 183, 2459-2469 (1996). (Pubitemid 26192355)
130. Lu L, Kaliyaperumal A, Boumpas DT, Datta SK. Major peptide autoepitopes for nucleosome-specific T cells of human lupus. J. Clin. Invest. 104, 345-355 (1999).
131. Riemekasten G, Weiss C, Schneider S et al. T cell reactivity against the SmD1 (83-119) C terminal peptide in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 61, 779-785 (2002).
132. O'Brien RM, Cram DS, Coppel RL, Harrison LC. T-cell epitopes on the 70-kDa protein of the (U1)RNP complex in autoimmune rheumatologic disorders. J. Autoimmun. 3, 747-757 (1990).
133. Fatenejad S, Bennett M, Moslehi J, Craft J. Influence of antigen organization on the development of lupus autoantibodies. Arthritis Rheum. 41, 603-612 (1998). (Pubitemid 28214978)